Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 1:13 AM
Study NCT ID:
NCT07448103
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-04
First Post:
2026-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hospital and Home Rehabilitation Based on Social Care Robotics and Artificial Intelligence for Pediatric Patients
Sponsor:
Inrobics Social Robotics, S.L.
Organization:
Study Overview
Official Title:
Hospital and Home Rehabilitation Based on Social Care Robotics and Artificial Intelligence for Pediatric Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INROBICS
Brief Summary:
This study describes a prospective, longitudinal, randomized controlled trial evaluating Inrobics Rehab, a CE-marked Class I medical device (reg. RPS/777/2021) that combines socially assistive robotics with virtual training for pediatric rehabilitation. The trial will assess usability, user experience, and clinical effectiveness. It is based on the premise that an interactive, motivating, monitored digital environment can improve engagement and adherence while enabling objective tracking of progress. The main hypothesis is that Inrobics Rehab will enhance motor, cognitive, and socio-emotional outcomes in children with acquired brain injury (ABI) and will be well accepted by users.
Participants will be children aged 7-16 years with confirmed ABI, adequate comprehension to follow instructions, clinical stability, and the ability to maintain sitting (with or without supports). Exclusion criteria include unstable upper-limb orthopedic injuries; severe pain, rigidity, or severe upper-limb spasticity; severe cardiopulmonary disease requiring constant monitoring; abnormal pre-ABI response to exertion; severe visual or cognitive impairment; disabling psychiatric disease; or any condition preventing safe participation. Additional safeguards are included due to the pediatric/vulnerable population.
Thirty participants will be recruited at Hospital Infantil Universitario Niño Jesús and split into two etiological cohorts (15 oncological, 15 non-oncological). Eligible patients will be enrolled by convenience sampling and randomized within each cohort to experimental or control arms (about half per arm) using sequentially numbered sealed envelopes based on a computer-generated random list. Outcome assessors are intended to remain blinded to allocation.
The experimental arm completes 30 sessions over 5 weeks: 15 supervised in-hospital sessions (Inrobics Rehab Clinic) and 15 home-based sessions (Inrobics Rehab Virtual). Hospital sessions are delivered three times per week for 30 minutes. Home sessions are completed three times per week on a tablet, guided by an interactive avatar, with gamification and automatic collection of performance metrics; a ±2-week window is allowed only to make up missed sessions. The control arm receives no intervention and undergoes evaluations at comparable timepoints; after study completion, controls may access the virtual platform for 1-3 months or complete the full program.
Assessments occur at baseline, post-intervention, and 3-month follow-up, with session-level monitoring of satisfaction, fatigue and/or pain. Heart rate is monitored only during hospital sessions (Polar Verity Sense). Outcomes include motor function (TCMS, Box \& Block, ABILHAND-Kids), neuropsychological and emotional measures (attention, working memory, depression/anxiety, executive functioning), health perception and burden (EQoL-5D-Y5L, pain VAS, fatigue, caregiver burden), and usability/engagement analytics (accuracy, reaction time, engagement, execution speed). Data will be pseudonymized, stored securely with restricted access, and retained for at least 10 years (or longer if required by medical device regulations).
Participants will be children aged 7-16 years with confirmed ABI, adequate comprehension to follow instructions, clinical stability, and the ability to maintain sitting (with or without supports). Exclusion criteria include unstable upper-limb orthopedic injuries; severe pain, rigidity, or severe upper-limb spasticity; severe cardiopulmonary disease requiring constant monitoring; abnormal pre-ABI response to exertion; severe visual or cognitive impairment; disabling psychiatric disease; or any condition preventing safe participation. Additional safeguards are included due to the pediatric/vulnerable population.
Thirty participants will be recruited at Hospital Infantil Universitario Niño Jesús and split into two etiological cohorts (15 oncological, 15 non-oncological). Eligible patients will be enrolled by convenience sampling and randomized within each cohort to experimental or control arms (about half per arm) using sequentially numbered sealed envelopes based on a computer-generated random list. Outcome assessors are intended to remain blinded to allocation.
The experimental arm completes 30 sessions over 5 weeks: 15 supervised in-hospital sessions (Inrobics Rehab Clinic) and 15 home-based sessions (Inrobics Rehab Virtual). Hospital sessions are delivered three times per week for 30 minutes. Home sessions are completed three times per week on a tablet, guided by an interactive avatar, with gamification and automatic collection of performance metrics; a ±2-week window is allowed only to make up missed sessions. The control arm receives no intervention and undergoes evaluations at comparable timepoints; after study completion, controls may access the virtual platform for 1-3 months or complete the full program.
Assessments occur at baseline, post-intervention, and 3-month follow-up, with session-level monitoring of satisfaction, fatigue and/or pain. Heart rate is monitored only during hospital sessions (Polar Verity Sense). Outcomes include motor function (TCMS, Box \& Block, ABILHAND-Kids), neuropsychological and emotional measures (attention, working memory, depression/anxiety, executive functioning), health perception and burden (EQoL-5D-Y5L, pain VAS, fatigue, caregiver burden), and usability/engagement analytics (accuracy, reaction time, engagement, execution speed). Data will be pseudonymized, stored securely with restricted access, and retained for at least 10 years (or longer if required by medical device regulations).
Detailed Description:
This study describes a randomized controlled clinical trial designed to evaluate the usability, user experience, and clinical effectiveness of Inrobics Rehab, a pediatric rehabilitation solution based on Socially Assistive Robotics (SAR) and Artificial Intelligence, in children and adolescents with Acquired Brain Injury (ABI) aged 7-16 years. The rationale is that SAR and virtual training can provide an interactive and motivating environment that may increase engagement and adherence, while enabling controlled, monitored exercises and objective follow-up of progress; however, evidence in pediatric ABI remains limited. The study hypothesis is that Inrobics Rehab can improve motor, cognitive, and socio-emotional outcomes in this population, while delivering a positive user experience with good usability and high adherence.
The study is planned as an experimental, longitudinal, prospective, controlled, randomized clinical trial using a CE-marked medical device (Inrobics Rehab; CE Class I, registration no. RPS/777/2021). It is embedded in a 36-month collaborative research project involving INROBICS, the Hospital Nacional de Parapléjicos, and the Hospital Infantil Universitario Niño Jesús (HIUNJ), where HIUNJ plays a central role in patient selection, clinical assessments, delivery of therapy sessions, and clinical data collection in a real-world hospital setting.
Participants will be pediatric patients with confirmed ABI receiving care at the HIUNJ Rehabilitation Service. Eligibility requires: age 7-16 years; sufficient comprehension to follow basic instructions and participate actively; confirmed acquired brain injury; clinical stability to engage in therapy; and ability to maintain independent sitting, with or without assistive supports (e.g., belts, wedges, trunk supports). Key exclusion criteria include unstable orthopedic injuries in the upper limbs (e.g., non-consolidated fractures or unstable osteosynthesis), severe pain/rigidity and/or severe upper-limb spasticity, severe pulmonary or cardiac disease requiring constant monitoring during exercise, a history of abnormal response to physical effort prior to ABI, severe visual impairment, severe cognitive impairment and/or disabling psychiatric disease, or any other condition judged by the medical team to prevent safe participation. The protocol emphasizes enhanced protection measures for this vulnerable population through reinforced consent/assent procedures, strict selection criteria, monitoring, and additional risk minimization.
A total sample of 30 pediatric ABI participants is planned, split into two etiological cohorts to support balanced comparisons: 15 with oncological etiology and 15 with non-oncological etiology. Initial selection is by convenience sampling among eligible patients routinely followed at HIUNJ; subsequently, within each etiological subgroup, participants are randomly allocated to an experimental or control arm, with approximately half in each arm. Randomization is implemented using sequentially numbered sealed envelopes containing group assignment (control vs intervention), based on a computer-generated random list; hospital evaluators remain blinded to group allocation to support objectivity in outcome collection. The protocol acknowledges that the theoretically estimated sample size to detect moderate effects would be larger, but justifies feasibility constraints and the relevance of the proposed sample in the context of pediatric SAR studies.
The experimental intervention consists of a structured rehabilitation program delivered through Inrobics Rehab Clinic (hospital) and Inrobics Rehab Virtual (home). The program includes 30 total sessions over 5 weeks of active intervention, distributed equally between 15 in-hospital sessions and 15 home-based virtual sessions, delivered in an alternating manner (weeks combining clinic and virtual work) to allow progressive adaptation while maintaining continuous clinical follow-up. Each hospital session lasts 30 minutes, with a planned frequency of 3 sessions per week, programmed and directed by a professional using the clinical platform and supervised throughout. In the home phase, participants complete 3 sessions per week via the virtual platform on a tablet, following exercises prescribed by the clinician and guided by an interactive virtual avatar; gamification elements are included to enhance motivation and participation, and the system records objective metrics to support monitoring of therapeutic progress and adaptation. A contingency window of ±2 additional weeks is allowed solely to recover missed sessions due to justified absences, without extending beyond this limit, to preserve a homogeneous "dose" of intervention and the internal validity of the design.
The control arm receives no therapeutic intervention within the trial; control participants complete the same evaluation schedule as the experimental group to enable between-group comparisons and help isolate the effect of the robotics/virtual intervention from external factors. To ensure fairness, the protocol includes a post-trial access option for control participants: after the clinical trial ends, they may access Inrobics Rehab Virtual for 1-3 months through a temporary license, or opt to undergo the full intervention program (hospital + home phases) if desired. At study completion, all participants in both groups receive an individualized final report summarizing assessment results over the program.
Outcome assessment is scheduled at baseline (pre-intervention), immediately after the intervention period (post-intervention at \~5 weeks for the intervention arm; at a comparable timepoint for controls), and at 3 months follow-up to determine whether observed changes are maintained. In addition, during the intervention, session-by-session ratings of satisfaction, fatigue, and/or pain are collected (hospital and home), and user-experience parameters are continuously recorded by the platform; heart rate is monitored only during hospital sessions. A dedicated Case Report Form (CRF) is included as an annex to standardize data capture and organization.
The protocol defines a broad set of outcomes covering motor performance, cognition/emotional status, health perception and burden, and usability/user experience. Motor efficacy is assessed using standardized measures including trunk control (Trunk Control Measurement Scale, TCMS), manual dexterity (Box \& Block, complemented by Leap Motion measures), and manual function (ABILHAND-Kids, with optional Jebsen-Taylor), as well as dominance (Edinburgh inventory) and upper-limb strength (Daniels and/or dynamometry). Neuropsychological and emotional domains include visual attention (perception/difference or "faces" tests), working memory (WISC-V digit span), depressive symptoms (Children's Depression Inventory for those under 14), anxiety (STAIC), and executive functioning (EFE inventory). Health perception and burden include pediatric quality of life (EQoL-5D-Y5L), pain (VAS), fatigue (EPInfant), and caregiver burden (Zarit). Usability and user experience are examined using both questionnaires and platform analytics, such as motor accuracy, reaction time, engagement (e.g., whether the user remains oriented toward the platform/tablet), aggregated performance metrics, and execution speed; physiological response to effort is assessed with heart-rate monitoring using Polar Verity Sense during hospital sessions. Satisfaction is assessed via SAM (child) and QUEST 2.0 (caregiver), and involvement/adherence-related constructs include a Hopkins measure of engagement with the training program.
Planned analyses include descriptive statistics and inferential comparisons across timepoints and between groups, selecting methods based on variable type and distribution, with standard significance thresholds; the protocol also identifies potential biases such as limited sample size, subjectivity in self-reported scales, and potential attrition particularly during the home phase.
Ethical conduct and data protection are addressed in line with relevant regulations and the specific needs of pediatric participants. The study is conducted according to the Declaration of Helsinki, and participation requires formal informed consent (with the option to withdraw at any time without affecting usual care). Data are pseudonymized using a sequential alphanumeric code assigned by inclusion order; all questionnaires, clinical measures, physiological records, and platform data are labeled only with this identifier, while the code-to-identity link is stored separately with restricted access. Pseudonymized datasets for analysis are stored in the institutional OneDrive environment with restricted, credential-based access, and cross-site data sharing is limited to pseudonymized information through controlled shared folders with the sponsor (INROBICS). Documentation generated for the clinical investigation is retained for at least 10 years after study completion (and potentially longer depending on applicable medical device regulatory requirements and market placement), with measures to ensure integrity, accessibility, and protection against loss, alteration, or unauthorized access.
The study is planned as an experimental, longitudinal, prospective, controlled, randomized clinical trial using a CE-marked medical device (Inrobics Rehab; CE Class I, registration no. RPS/777/2021). It is embedded in a 36-month collaborative research project involving INROBICS, the Hospital Nacional de Parapléjicos, and the Hospital Infantil Universitario Niño Jesús (HIUNJ), where HIUNJ plays a central role in patient selection, clinical assessments, delivery of therapy sessions, and clinical data collection in a real-world hospital setting.
Participants will be pediatric patients with confirmed ABI receiving care at the HIUNJ Rehabilitation Service. Eligibility requires: age 7-16 years; sufficient comprehension to follow basic instructions and participate actively; confirmed acquired brain injury; clinical stability to engage in therapy; and ability to maintain independent sitting, with or without assistive supports (e.g., belts, wedges, trunk supports). Key exclusion criteria include unstable orthopedic injuries in the upper limbs (e.g., non-consolidated fractures or unstable osteosynthesis), severe pain/rigidity and/or severe upper-limb spasticity, severe pulmonary or cardiac disease requiring constant monitoring during exercise, a history of abnormal response to physical effort prior to ABI, severe visual impairment, severe cognitive impairment and/or disabling psychiatric disease, or any other condition judged by the medical team to prevent safe participation. The protocol emphasizes enhanced protection measures for this vulnerable population through reinforced consent/assent procedures, strict selection criteria, monitoring, and additional risk minimization.
A total sample of 30 pediatric ABI participants is planned, split into two etiological cohorts to support balanced comparisons: 15 with oncological etiology and 15 with non-oncological etiology. Initial selection is by convenience sampling among eligible patients routinely followed at HIUNJ; subsequently, within each etiological subgroup, participants are randomly allocated to an experimental or control arm, with approximately half in each arm. Randomization is implemented using sequentially numbered sealed envelopes containing group assignment (control vs intervention), based on a computer-generated random list; hospital evaluators remain blinded to group allocation to support objectivity in outcome collection. The protocol acknowledges that the theoretically estimated sample size to detect moderate effects would be larger, but justifies feasibility constraints and the relevance of the proposed sample in the context of pediatric SAR studies.
The experimental intervention consists of a structured rehabilitation program delivered through Inrobics Rehab Clinic (hospital) and Inrobics Rehab Virtual (home). The program includes 30 total sessions over 5 weeks of active intervention, distributed equally between 15 in-hospital sessions and 15 home-based virtual sessions, delivered in an alternating manner (weeks combining clinic and virtual work) to allow progressive adaptation while maintaining continuous clinical follow-up. Each hospital session lasts 30 minutes, with a planned frequency of 3 sessions per week, programmed and directed by a professional using the clinical platform and supervised throughout. In the home phase, participants complete 3 sessions per week via the virtual platform on a tablet, following exercises prescribed by the clinician and guided by an interactive virtual avatar; gamification elements are included to enhance motivation and participation, and the system records objective metrics to support monitoring of therapeutic progress and adaptation. A contingency window of ±2 additional weeks is allowed solely to recover missed sessions due to justified absences, without extending beyond this limit, to preserve a homogeneous "dose" of intervention and the internal validity of the design.
The control arm receives no therapeutic intervention within the trial; control participants complete the same evaluation schedule as the experimental group to enable between-group comparisons and help isolate the effect of the robotics/virtual intervention from external factors. To ensure fairness, the protocol includes a post-trial access option for control participants: after the clinical trial ends, they may access Inrobics Rehab Virtual for 1-3 months through a temporary license, or opt to undergo the full intervention program (hospital + home phases) if desired. At study completion, all participants in both groups receive an individualized final report summarizing assessment results over the program.
Outcome assessment is scheduled at baseline (pre-intervention), immediately after the intervention period (post-intervention at \~5 weeks for the intervention arm; at a comparable timepoint for controls), and at 3 months follow-up to determine whether observed changes are maintained. In addition, during the intervention, session-by-session ratings of satisfaction, fatigue, and/or pain are collected (hospital and home), and user-experience parameters are continuously recorded by the platform; heart rate is monitored only during hospital sessions. A dedicated Case Report Form (CRF) is included as an annex to standardize data capture and organization.
The protocol defines a broad set of outcomes covering motor performance, cognition/emotional status, health perception and burden, and usability/user experience. Motor efficacy is assessed using standardized measures including trunk control (Trunk Control Measurement Scale, TCMS), manual dexterity (Box \& Block, complemented by Leap Motion measures), and manual function (ABILHAND-Kids, with optional Jebsen-Taylor), as well as dominance (Edinburgh inventory) and upper-limb strength (Daniels and/or dynamometry). Neuropsychological and emotional domains include visual attention (perception/difference or "faces" tests), working memory (WISC-V digit span), depressive symptoms (Children's Depression Inventory for those under 14), anxiety (STAIC), and executive functioning (EFE inventory). Health perception and burden include pediatric quality of life (EQoL-5D-Y5L), pain (VAS), fatigue (EPInfant), and caregiver burden (Zarit). Usability and user experience are examined using both questionnaires and platform analytics, such as motor accuracy, reaction time, engagement (e.g., whether the user remains oriented toward the platform/tablet), aggregated performance metrics, and execution speed; physiological response to effort is assessed with heart-rate monitoring using Polar Verity Sense during hospital sessions. Satisfaction is assessed via SAM (child) and QUEST 2.0 (caregiver), and involvement/adherence-related constructs include a Hopkins measure of engagement with the training program.
Planned analyses include descriptive statistics and inferential comparisons across timepoints and between groups, selecting methods based on variable type and distribution, with standard significance thresholds; the protocol also identifies potential biases such as limited sample size, subjectivity in self-reported scales, and potential attrition particularly during the home phase.
Ethical conduct and data protection are addressed in line with relevant regulations and the specific needs of pediatric participants. The study is conducted according to the Declaration of Helsinki, and participation requires formal informed consent (with the option to withdraw at any time without affecting usual care). Data are pseudonymized using a sequential alphanumeric code assigned by inclusion order; all questionnaires, clinical measures, physiological records, and platform data are labeled only with this identifier, while the code-to-identity link is stored separately with restricted access. Pseudonymized datasets for analysis are stored in the institutional OneDrive environment with restricted, credential-based access, and cross-site data sharing is limited to pseudonymized information through controlled shared folders with the sponsor (INROBICS). Documentation generated for the clinical investigation is retained for at least 10 years after study completion (and potentially longer depending on applicable medical device regulatory requirements and market placement), with measures to ensure integrity, accessibility, and protection against loss, alteration, or unauthorized access.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R-0024/25 | OTHER | CEIm Hospital Universitario Niño Jesús | View |